BIOTRONIK and Egg Medical Form Strategic Alliance to Improve Radiation Protection for Interventional Healthcare Workers

BIOTRONIK, a global leader in cardiovascular, endovascular, and neuromodulation solutions, today announced it is partnering with Egg Medical, Inc., a global leader in radiation protection technology, to co-sell Egg Medical’s EggNest™ Radiation Protection Systems for healthcare workers in the United States.

The EggNest Systems (EggNest XR, EggNest Protect & EggNest Complete) are innovative radiation protection platforms that can be used across a wide variety of fluoroscopy procedure types without impacting workflow. The EggNest Systems are the only products commercially available in the US able to protect everyone in the interventional suite. Radiation reductions of up to 97% are possible with EggNest XR and EggNest Protect, and up to 99% reductions are possible with EggNest Complete.1

“Partnering with companies like Egg Medical in the radiation protection space allows BIOTRONIK to bring our vision of ‘Excellence for Life’ to healthcare professionals as well as their patients.  These products will allow us to bring a safer environment to every member of the EP lab, Cath lab, and other procedure suites,” said Matt Roberts, VP, National and Corporate Accounts at BIOTRONIK.

“We are thrilled to partner with BIOTRONIK, who has been focused on providing radiation protection to their customers for many years. This partnership expands our ability to provide protection for everyone in the procedure room across the US,” said Gavin Philipps, Chief Commercial Officer at Egg Medical.

More Articles from the Medical Industry

Korea Innovation QuickFire Challenge: Targeting Neuroscience

Overview Despite significant advances in understanding and treating nervous system disorders, millions of people worldwide continue to live with neurodegenerative …

Medical Fair Thailand 2025, Global healthcare innovations for the future

Experience the Future of Healthcare Visit over 1,000 global exhibitors from more than 40 countries, explore 20+ international pavilions and …

Unlocking Urologic Oncology Innovation QuickFire Challenge

Overview As our population ages, the incidence of bladder and prostate cancers (commonly known as Genitourinary or GU cancers) continues …

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

QIAcuity digital PCR kits, assays and protocols for lentivirus-based therapies support quality control in cell and gene therapy manufacturing Expansion …
Share via
Copy link